Precision BioSciences, Inc. (NASDAQ:DTIL) Short Interest Up 11.7% in December

Precision BioSciences, Inc. (NASDAQ:DTIL) saw a significant increase in short interest during the month of December. As of December 31st, there was short interest totalling 306,700 shares, an increase of 11.7% from the December 15th total of 274,500 shares. Currently, 8.2% of the shares of the stock are sold short. Based on an average trading volume of 418,600 shares, the short-interest ratio is currently 0.7 days.

Precision BioSciences Stock Up 5.1 %

DTIL traded up $0.24 on Monday, hitting $4.96. 183,493 shares of the company were exchanged, compared to its average volume of 183,149. The company has a market cap of $38.04 million, a PE ratio of 82.68 and a beta of 1.51. Precision BioSciences has a 12 month low of $3.61 and a 12 month high of $19.43. The stock’s fifty day moving average is $5.77 and its 200-day moving average is $8.10. The company has a debt-to-equity ratio of 0.34, a quick ratio of 9.22 and a current ratio of 9.22.

Analyst Ratings Changes

A number of brokerages have issued reports on DTIL. BMO Capital Markets raised shares of Precision BioSciences from a “market perform” rating to an “outperform” rating and set a $34.00 price objective on the stock in a research note on Friday, January 10th. HC Wainwright reiterated a “buy” rating and issued a $60.00 price objective on shares of Precision BioSciences in a report on Friday, January 10th.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Precision BioSciences stock. Janus Henderson Group PLC grew its stake in shares of Precision BioSciences, Inc. (NASDAQ:DTIL) by 10.9% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 702,069 shares of the company’s stock after acquiring an additional 68,943 shares during the quarter. Janus Henderson Group PLC owned about 9.15% of Precision BioSciences worth $6,322,000 as of its most recent SEC filing. Institutional investors own 37.99% of the company’s stock.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.